Pharma and biotech companies can't justify IPR opt outs, but you can see why they are asking for them
Register to access two of our subscriber only articles per month.
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Author | Editor-in-chief
@IAM_Alerts Beijing wants cross-border IP trade to increase: policymakers target $54 billion in IP royalty imports/exports by 2… https://t.co/9oPIjvEF8e Read more
@IAM_Alerts RT @FOSSpatents: Undoing Trump Administration policies, one at a time. Read more
@IAM_Alerts Leahy aims to reverse USPTO’s discretionary denials in new PTAB reform bill https://t.co/tfj6h9AScK https://t.co/cl8Y0cCEZ3 Read more
@IAM_Alerts More details of the proposed legislation's content have been shared by the Leahy team. We will have them on the IAM… https://t.co/D4VjaljD5M Read more